Clinical Effectiveness of Decitabine Combined with Reduced FLAG Regimen in the Treatment of Senile Patients with High-Risk Acute Myeloid Leukemia
OBJECTIVE: To explore the efficacy and adverse reactions of decitabine combined with reduction FLAG regimen on the senile patients with high-risk AML.
METHODS: 12 senile patients with high-risk AML received decitabine combined with reduced FLAG regimen (decitabine 20 mg/m2, intravenous drip, qd, d 1-5; fludarabine 30 mg/m2, intravenous drip lasts 30 min, qd, d 3-6; Ara-C 1 g/m2, intravenous drip, qd, d 3-6; and G-CSF 300 μg/d, subcu- taneous injection, d 2 to neutrophils reached the lowest return to＞1.0×109/L) in our study. The efficacy and adverse reactions of this regimen were analyzed.
RESULTS: 9 patients achieved complete remission(CR) after one course of decitabine combined with reduced FLAG regimen, 2 patients achieved partial remission (PR) and 1 patient reached a stable disease (SD). The overall response rate was 92%. The median follow-up period was 7.4 months ranged from 3 to 12 months. The median survival time for all patients was 6.4 months. The main treatment-related toxicities were myelosuppression and infection due to neutropenia. Severe non-hematologic toxicities were not observed in these patients, and there was no treatment-related mortality.
CONCLUSION: Decitabine combined with reduced FLAG regimen has a definite clinical efficacy in the treatment of senile patients with high-risk AML. This regimen, as induction remission regimen, can effectively improve the CR rate and reduce the adverse reactions. Therefore, it may be used as one of the preferred induction remission regimen to treat the senile patients with high-risk AML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Zhongguo shi yan xue ye xue za zhi - 28(2020), 5 vom: 01. Okt., Seite 1440-1444 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Qi, Yao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04079A1RDZ |
|---|
| Anmerkungen: |
Date Completed 20.10.2020 Date Revised 20.10.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.19746/j.cnki.issn.1009-2137.2020.05.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31637377X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31637377X | ||
| 003 | DE-627 | ||
| 005 | 20231225160936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.19746/j.cnki.issn.1009-2137.2020.05.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM31637377X | ||
| 035 | |a (NLM)33067934 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Qi, Yao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Effectiveness of Decitabine Combined with Reduced FLAG Regimen in the Treatment of Senile Patients with High-Risk Acute Myeloid Leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2020 | ||
| 500 | |a Date Revised 20.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To explore the efficacy and adverse reactions of decitabine combined with reduction FLAG regimen on the senile patients with high-risk AML | ||
| 520 | |a METHODS: 12 senile patients with high-risk AML received decitabine combined with reduced FLAG regimen (decitabine 20 mg/m2, intravenous drip, qd, d 1-5; fludarabine 30 mg/m2, intravenous drip lasts 30 min, qd, d 3-6; Ara-C 1 g/m2, intravenous drip, qd, d 3-6; and G-CSF 300 μg/d, subcu- taneous injection, d 2 to neutrophils reached the lowest return to＞1.0×109/L) in our study. The efficacy and adverse reactions of this regimen were analyzed | ||
| 520 | |a RESULTS: 9 patients achieved complete remission(CR) after one course of decitabine combined with reduced FLAG regimen, 2 patients achieved partial remission (PR) and 1 patient reached a stable disease (SD). The overall response rate was 92%. The median follow-up period was 7.4 months ranged from 3 to 12 months. The median survival time for all patients was 6.4 months. The main treatment-related toxicities were myelosuppression and infection due to neutropenia. Severe non-hematologic toxicities were not observed in these patients, and there was no treatment-related mortality | ||
| 520 | |a CONCLUSION: Decitabine combined with reduced FLAG regimen has a definite clinical efficacy in the treatment of senile patients with high-risk AML. This regimen, as induction remission regimen, can effectively improve the CR rate and reduce the adverse reactions. Therefore, it may be used as one of the preferred induction remission regimen to treat the senile patients with high-risk AML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Decitabine |2 NLM | |
| 650 | 7 | |a 776B62CQ27 |2 NLM | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Zhao, Ming-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yi-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Rui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo shi yan xue ye xue za zhi |d 2000 |g 28(2020), 5 vom: 01. Okt., Seite 1440-1444 |w (DE-627)NLM122963113 |x 1009-2137 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:5 |g day:01 |g month:10 |g pages:1440-1444 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 5 |b 01 |c 10 |h 1440-1444 | ||